Izertis drives its expansion: increased financing, more capital, and a new independent director on the Board
Izertis’ General Shareholders’ Meeting has approved the appointment of Isabel Lozano Fernández as a new independent director, a move that strengthens the corporate governance of the technology consultancy during a phase of expansion. The meeting also overwhelmingly endorsed the strong growth recorded in 2025 and approved new financial and corporate transactions.
With more than three decades of experience in senior management, financing, and corporate governance, Isabel has led companies such as Atrys Health (which she co-founded and managed for more than 18 years) and has held key positions at PharmaMar and Grupo Zeltia. She currently serves on the Board of Directors of Hifas da Terra.
Her appointment brings a combination of strategic vision, an international outlook, and financial strength.
Isabel Lozano Fernández, new independent director
Shareholders also approved both the individual and consolidated annual accounts for 2025, a year in which Izertis consolidated its growth and strengthened its financial position.
The company achieved revenues of €166.9 million, representing a 20.9% increase, and a normalised EBITDA of €24.1 million, up 16.8%, maintaining a margin of 14.5%, above the sector average.
These results reflect the evolution of a model that combines organic growth and acquisitions, supported by the integration of companies during the year across both domestic and international markets. These include the UK firms Assured Thought and May Business Consulting (MBC), the Central American group Coderland, and the Spanish companies ICALIA and ICATD.
At the same time, Izertis strengthened its liquidity, with cash close to €54 million, and kept debt under control, with a net debt-to-EBITDA ratio of 2.7x at year-end. This solid financial base enables the company to pursue new projects aligned with its strategic roadmap.
Furthermore, it was reported that EthiFinance Ratings has reaffirmed Izertis’ BB+ rating and has also upgraded its outlook from stable to positive, a change that strengthens confidence in the group’s performance and in its ability to continue enhancing its financial profile.
Key transactions and new financial tools
During the General Meeting, shareholders authorised the Board to deploy a broad range of financial instruments aimed at accelerating growth.
Shareholders have authorised the Board to deploy a broad range of financial instruments
These include entering a syndicated financing agreement for up to €140 million. They also approved the possibility of capital increases of up to 50% of share capital, and the issuance of financial instruments such as bonds or warrants over a five-year period.
These measures strengthen the company’s capacity to undertake new investments, corporate transactions, and international expansion projects.
In terms of corporate governance, the Meeting approved the reappointment of PricewaterhouseCoopers as auditor for the 2027 financial year. It also approved a long-term incentive plan for 2026–2030 aimed at executive directors and key executives, with a maximum of 700,000 shares, aligned with sustainable value creation and the group’s strategic objectives.
The General Shareholders’ Meeting has thus endorsed a set of measures that reinforce both Izertis’ operational growth and its governance structure, at a time when the technology consultancy seeks to consolidate its position as one of Europe’s leading technology players.
The consultancy’s Business Plan targets revenues of €500 million and a normalised EBITDA of €65 million by 2030, supported by both organic and inorganic growth, international expansion, and the development of capabilities in cybersecurity, data, and artificial intelligence, among others.